CAR-T TherapyHaematological gnancy and Forecast Market

List of Tables
Table 1. CAR-T Therapy in Haematological Malignancy Market Opportunities & Trends in Global Market
Table 2. CAR-T Therapy in Haematological Malignancy Market Drivers in Global Market
Table 3. CAR-T Therapy in Haematological Malignancy Market Restraints in Global Market
Table 4. Key Players of CAR-T Therapy in Haematological Malignancy in Global Market
Table 5. Top CAR-T Therapy in Haematological Malignancy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global CAR-T Therapy in Haematological Malignancy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Companies, 2017-2022
Table 8. Global Companies CAR-T Therapy in Haematological Malignancy Product Type
Table 9. List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2023-2028
Table 30. Celgene (Juno Therapeutics) Corporate Summary
Table 31. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 32. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 35. Novartis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 36. Gilead (Kite Pharma) Corporate Summary
Table 37. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 38. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer CAR-T Therapy in Haematological Malignancy Product Offerings
Table 41. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 42. CARsgen Therapeutics Corporate Summary
Table 43. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 44. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 45. Autolus Therapeutics Corporate Summary
Table 46. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 47. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 48. Aurora BioPharma Corporate Summary
Table 49. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offerings
Table 50. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 51. Sorrento Therapeutics Corporate Summary
Table 52. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 53. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 54. Mustang Bio Corporate Summary
Table 55. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 56. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 57. Bluebird Bio Corporate Summary
Table 58. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 59. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 60. Collectis Corporate Summary
Table 61. Collectis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 62. Collectis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 63. Allogene Therapeutics Corporate Summary
Table 64. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 65. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
Table 66. Celyad Corporate Summary
Table 67. Celyad CAR-T Therapy in Haematological Malignancy Product Offerings
Table 68. Celyad CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. CAR-T Therapy in Haematological Malignancy Segment by Type in 2021
Figure 2. CAR-T Therapy in Haematological Malignancy Segment by Application in 2021
Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2021
Figure 8. By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 9. By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 10. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 11. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 12. US CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 16. Germany CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 17. France CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 24. China CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 28. India CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 30. Brazil CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2017-2028
Figure 33. Turkey CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2017-2028
Figure 37. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Collectis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Celyad CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)